 |
200 Diseases |  |
195 Trials |
|
195 Trials |  |
21272 News |  |
| 12345678910111213...225226» |
- | Journal: Tuberculous Meningitis and Hemophagocytic Lymphohistiocytosis in a Patient on Adalimumab: Diagnostic Challenges in the Setting of Suspected Non-Tuberculous Mycobacteria Co-Infection. (Pubmed Central) - Jul 10, 2025
The increased risk of opportunistic infections associated with long-term tumour necrosis factor-alpha inhibitor use necessitates ongoing infection screening.Hemophagocytic lymphohistiocytosis triggered by mycobacterial infections requires prompt recognition and targeted treatment.Polymerase chain reaction results should be interpreted with caution in complex clinical scenarios, as deoxyribonucleic acid detection may indicate colonization rather than active infection.
- || Remicade (infliximab) / J&J, Stelara (ustekinumab) / J&J, Humira (adalimumab) / AbbVie
Clinical, Retrospective data, Journal: Anti-IL 12/23 versus Anti-Tumor Necrosis Factor-? in Patients with Biologically Na (Pubmed Central) - Jul 10, 2025
This meta-analysis found no significant differences in clinical remission, corticosteroid-free remission, endoscopic remission, or endoscopic response within 52 weeks between ustekinumab and anti-TNF-? agents in biologic-na
- Humira (adalimumab) / AbbVie
PULMONARY MELIOIDOSIS WITH LYMPHADENOPATHY IN PATIENT WITH CROHN'S DISEASE ON ADALIMUMAB: A CASE REPORT (Science Lounge) - Jul 9, 2025 - Abstract #UEGW2025UEGW_3076;
- Humira (adalimumab) / AbbVie
EARLY ADALIMUMAB TROUGH LEVELS PREDICT CLINICAL AND BIOCHEMICAL REMISSION IN PATIENTS WITH CROHN'S DISEASE (Science Lounge) - Jul 9, 2025 - Abstract #UEGW2025UEGW_3051;
- Humira (adalimumab) / AbbVie
RARE CASE OF ADALIMUMAB-INDUCED LUPUS ERYTHEMATOSUS COMPLICATING ILEOCOLONIC CROHN'S DISEASE (Science Lounge) - Jul 9, 2025 - Abstract #UEGW2025UEGW_3032;
- | Journal: Vulvar Crohn disease: A case report. (Pubmed Central) - Jul 9, 2025
She was experiencing painful vulvar fissures, which ultimately resulted in a diagnosis of vulvar Crohn's disease. The patient's symptoms had resolved at the most recent follow-up visit with treatment, including adalimumab 40 mg, metronidazole 500 mg, and intralesional triamcinolone acetonide injections.
- Humira (adalimumab) / AbbVie
LONG-TERM OUTCOMES OF INCREASED VERSUS CONVENTIONAL ADALIMUMAB DOSE INTERVAL FOR PATIENTS WITH CROHN'S DISEASE IN STABLE REMISSION: 3-YEAR FOLLOW-UP OF THE RANDOMIZED CONTROLLED LADI TRIAL (Poster Stage 3) - Jul 8, 2025 - Abstract #UEGW2025UEGW_852;
- Humira (adalimumab) / AbbVie
CHANGING THE COURSE OF CROHN'S DISEASE WITH AN EARLY USE OF ADALIMUMAB: THE CURE STUDY FROM THE GETAID (Room Helsinki) - Jul 8, 2025 - Abstract #UEGW2025UEGW_500;
- | Rinvoq (upadacitinib) / AbbVie, minoxidil / Generic mfg., Humira (adalimumab) / AbbVie
Journal: Management of comorbid Crohn's disease and alopecia universalis with upadacitinib and oral minoxidil. (Pubmed Central) - Jul 8, 2025
This case highlights the potential of JAK is to address potentially overlapping immune-mediated disorders and suggests that upadacitinib, in combination with oral minoxidil, may promote rapid AU remission. These findings may inform future treatment approaches for complex autoimmune presentations.
- || Clinical, Retrospective data, Review, Journal: Risk of new-onset and recurrent uveitis with different biologics for ankylosing spondylitis: a network meta-analysis. (Pubmed Central) - Jul 7, 2025
Etanercept increased the risk of uveitis compared to other TNF-? inhibitors.
- | Journal: New therapeutic options in sarcoidosis. (Pubmed Central) - Jul 7, 2025
inhibitors. Despite many challenges, well designed studies are warranted to investigate new therapeutic options in sarcoidosis, particularly in patients with refractory forms or unacceptable side-effects with third-line treatment.
- ||| Journal, Adverse events: Abortion adverse events associated with adalimumab, etanercept, ustekinumab, and dupilumab during pregnancy: A pharmacovigilance study based on FDA adverse event reporting system. (Pubmed Central) - Jul 6, 2025
In conclusion, adalimumab, etanercept, and ustekinumab are associated with an increased risk of abortion-related adverse pregnancy outcomes, though the signals remain relatively weak. Further large-scale studies are needed to provide more definitive evidence.
- | Humira (adalimumab) / AbbVie
Journal: Assessing early therapeutic drug monitoring of adalimumab as a predictor of treatment efficacy and immunogenicity in rheumatic diseases. (Pubmed Central) - Jul 4, 2025
Further large-scale studies are needed to provide more definitive evidence. No abstract available
- | methotrexate / Generic mfg., Humira (adalimumab) / AbbVie
Journal: A Case of Tattoo-related Sarcoidosis with Generalized Lymph Node Enlargement. (Pubmed Central) - Jul 4, 2025
We noted tattoos (which were created10 years earlier) on the left upper arm and forearm. It was hypothesized that some component in the tattoos had triggered a systemic foreign body reaction by macrophages, resulting in sarcoidosis.Treatment with steroids was ineffective, but additional treatment with methotrexate plus adalimumab was successful.
- | Rinvoq (upadacitinib) / AbbVie, Humira (adalimumab) / AbbVie, Cosentyx (secukinumab) / Novartis
Journal: A Case of Refractory Hidradenitis Suppurativa Successfully Treated With Upadacitinib. (Pubmed Central) - Jul 4, 2025
As several Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathways are involved in the pathogenesis of HS, JAK inhibitors represent a promising therapeutic target. Herein, we present a case of severe hidradenitis suppurativa treated with upadacitinib following the failure of adalimumab and secukinumab.
- || Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
Retrospective data, Review, Journal: Comparison Between Adalimumab and Infliximab in Perianal Crohn's Disease: A Systematic Review and Meta-Analysis. (Pubmed Central) - Jul 4, 2025
In this systematic review and meta-analysis, ADA was not inferior to IFX in effectiveness for the treatment of perianal CD. Head-to-head prospective and randomized controlled studies comparing ADA and IFX are necessary to validate the findings of this study.
- || Clinical, Retrospective data, Journal: Efficacy and Safety of Medical Interventions for Moderate to Severe Hidradenitis Suppurativa: A Living Systematic Review and Network Meta-Analysis. (Pubmed Central) - Jul 2, 2025
The percentage of patients discontinuing treatment due to adverse events ranged from 0% to 10% in the placebo groups, 0% to 4% in the adalimumab (40 mg, once per week) groups, and 0% to 15% (ropsacitinib) in the other active treatment groups. This network meta-analysis provides evidence for the comparative efficacy and safety of currently approved and pipeline medications for moderate to severe HS in the absence of head-to-head trials.
- | Journal, Real-world evidence: Evolution of Drug Supply for Psoriasis from 2010 to 2022 - Real-World Claims Data Analysis in Germany. (Pubmed Central) - Jul 2, 2025
Adalimumab was the most frequently prescribed systemic drug, followed by ustekinumab and secukinumab. The highest mean costs per-person were for ustekinumab (
- | Journal: Identifying Key Genes and Approved Medications Associated with Major Depressive Disorder Using Network Analysis and Systems Biology. (Pubmed Central) - Jul 1, 2025
This study provides a new vision of the pathogenesis and treatment of MDD. However, further experimental and clinical studies are necessary.
- | Journal: Trend in the use of biological drugs in pediatric patients with immune-mediated inflammatory diseases: insight from the large-scale Italian VALORE project. (Pubmed Central) - Jul 1, 2025
After one year from the treatment start, more than 70% of JIA patients using either adalimumab or etanercept were still on treatment, while persistence rates in IBDs were lower (ranging from 57.4% to 65.0%). Findings of this study show the potential of the VALORE network to provide enough exposure data to investigate the risk of serious infections for adalimumab, etanercept, and infliximab.
- | Humira (adalimumab) / AbbVie
Journal, Real-world evidence: ADOLESBIO-HS: A real-world multicenter case series on the effectiveness and safety of Adalimumab in adolescents with moderate-to-severe Hidradenitis Suppurativa. (Pubmed Central) - Jul 1, 2025
Findings of this study show the potential of the VALORE network to provide enough exposure data to investigate the risk of serious infections for adalimumab, etanercept, and infliximab. Adalimumab showed a similar safety profile in adolescents with moderate-to-severe HS as in adults, with better effectiveness data.
- || Humira (adalimumab) / AbbVie
PK/PD data, Journal: Physiologically-based pharmacokinetic modeling to predict the exposure and provide dosage regimens of adalimumab in patients with juvenile idiopathic arthritis. (Pubmed Central) - Jun 30, 2025
For pediatric patients with JIA, age- and weight-based dosing is recommended to achieve trough concentrations comparable to those in adults. A PBPK model for adalimumab in pediatric patients with JIA was developed, providing a basis for personalized dosing regimens in this population.
- || Review, Journal: Hidradenitis Suppurativa Treatment During Pregnancy and Lactation: Navigating Challenges. (Pubmed Central) - Jun 30, 2025
Conversely, while newly approved HS medications such as secukinumab and bimekizumab show promise for the general population, further research is necessary to evaluate their safety profiles in pregnant and breastfeeding individuals. The scant research available on HS in pregnant and lactating women, also shown by our systematic literature review, highlights the need for a comprehensive investigation into the safety, efficacy, and suitability of management strategies.
- Humira (adalimumab) / AbbVie
BIOLOGIC BACKFIRE: PNEUMOCYSTIS JIROVECII PNEUMONIA IN A PATIENT ON ADALIMUMAB () - Jun 30, 2025 - Abstract #CHEST2025CHEST_2633;
- Humira (adalimumab) / AbbVie
PULMONARY HISTOPLASMOSIS IN A PATIENT WITH ULCERATIVE COLITIS ON ADALIMUMAB THERAPY () - Jun 30, 2025 - Abstract #CHEST2025CHEST_2618;
- Humira (adalimumab) / AbbVie
FROM DORMANT TO DANGEROUS: TUBERCULOSIS REACTIVATION WITH ADALIMUMAB USE () - Jun 30, 2025 - Abstract #CHEST2025CHEST_1591;
- Humira (adalimumab) / AbbVie
HISTOPLASMA PNEUMONIA IN A PATIENT ON ADALIMUMAB WITH CHECKPOINT INHIBITOR PNEUMONITIS () - Jun 30, 2025 - Abstract #CHEST2025CHEST_1587;
- || Retrospective data, Review, Journal: Switching biologic agent in patients with psoriasis: a systematic review and meta-analysis. (Pubmed Central) - Jun 27, 2025
However, in the long term, both switching strategies are effective and safe. This study also shows that
- | Journal: Refractory Acrodermatitis Continua of Hallopeau in a Pediatric Patient: Unveiling Underlying Mixed Connective Tissue Disorder. (Pubmed Central) - Jun 27, 2025
Steps for diagnostic workup and treatment may provide clinical benefits to patients and serve as a reference for other clinicians. The course of treatment for ACH and MCTD in the pediatric and adolescent population is discussed.
- | Remicade (infliximab) / J&J, thalidomide / Generic mfg., Humira (adalimumab) / AbbVie
Retrospective data, Journal: Clinical characteristics and treatment strategies for A20 haploinsufficiency in Japan: a national epidemiological survey. (Pubmed Central) - Jun 27, 2025
However, secondary failure of MTDs was a significant refractory-related factor in HA20 patients in Japan. Although anti-interferon therapies, thalidomide, and HCT might be potential treatment options, the results of this study suggest that further research is necessary to establish suitable treatments for HA20, especially for those with refractory disease.
- | Journal, Gene Signature, Heterogeneity: Metabolism and Response to Stress Gene Signatures Reveal Ulcerative Colitis Heterogeneity and Identify Patients With Increased Response to Therapy. (Pubmed Central) - Jun 27, 2025
We identified and evaluated a novel, multi-dimensional signature gene set to characterize previously undefined heterogeneity in patients with UC and identify patients less likely to respond to therapy. This approach offers potential utility to define clinical trial populations, enrich for clinical responders, and identify difficult-to-treat populations for therapeutic development.
- | Orencia (abatacept) / BMS, methotrexate / Generic mfg., Humira (adalimumab) / AbbVie
Journal, HEOR: Comparative Effectiveness of Abatacept versus Adalimumab in Shared Epitope positive and negative Rheumatoid Arthritis patients. (Pubmed Central) - Jun 26, 2025
This approach offers potential utility to define clinical trial populations, enrich for clinical responders, and identify difficult-to-treat populations for therapeutic development. We find no evidence that HLA-typing is clinically useful to support prescription decisions for these two drugs.
- | Remicade (infliximab) / J&J, prednisone / Generic mfg., Humira (adalimumab) / AbbVie
Journal: Epidemiology, Clinical Features and Treatment of Neurosarcoidosis in Northern Spain. (Pubmed Central) - Jun 26, 2025
We find no evidence that HLA-typing is clinically useful to support prescription decisions for these two drugs. Twenty-five patients (86.2%) received oral glucocorticoids (mean
- | Humira (adalimumab) / AbbVie
Journal: Surgical Deroofing in the Management of Hidradenitis Suppurativa Alone or as an Adjunct to Medical Therapies. (Pubmed Central) - Jun 25, 2025
Deroofing is a safe and effective surgical technique that can be used for acute and chronic recurrent/fixed lesions in Hurley I-III disease alone or as an adjunct to systemic therapies. Deroofing has a low recurrence rate, reduces pain, and improves QoL.
- || Remicade (infliximab) / J&J, Entyvio (vedolizumab) / Takeda, Humira (adalimumab) / AbbVie
Clinical, Retrospective data, Review, Journal: Risk of new or recurrent cancer during treatment with biologics in patients with immune-mediated inflammatory diseases and previous cancer: a meta-analysis. (Pubmed Central) - Jun 25, 2025
The results are reassuring to patients and physicians prescribing biologics to patients with IMIDs. However, further studies are needed especially on newer biologics and decision on initiation of biologics in patients with cancers should be based on an individual assessment.
- | Remicade (infliximab) / J&J, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
Journal: Lessons from TNF-? Inhibitor-induced Alopecia Areata: Does TNF-? Operate as a Hair Follicle Immune Privilege Guardian under Inflammatory Conditions? (Pubmed Central) - Jun 25, 2025
Thus, TNFi may weaken HF IP and facilitate the onset of AA. We delineate how this provocative hypothesis can be tested experimentally, and why it is both biologically and clinically important to do so.
- | Humira (adalimumab) / AbbVie, Xolair (omalizumab) / Roche, Novartis
Journal: Potential medicine waste in the process of outpatients receiving cost-free medicines from medicine pick-up lockers in the North Denmark region. (Pubmed Central) - Jun 24, 2025
Our analysis solely focuses on waste associated with medications left uncollected from medicine pick-up lockers. Addressing the impact of medicine waste in a hospital setting requires a comprehensive approach, thus future studies should also focus on other sites relevant for medication waste as, for example, the patient's household.
- | Remicade (infliximab) / J&J, prednisone / Generic mfg., Humira (adalimumab) / AbbVie
Journal: Safety and Efficacy of High-Dosage Infliximab in Recalcitrant Retinal Vasculitis. (Pubmed Central) - Jun 24, 2025
We evaluated the long-term safety and efficacy of high-dosage infliximab and biosimilars (IFX+) in recalcitrant, non-infectious inflammatory retinal vasculitis (RV) after antimetabolite and adalimumab failure...Efficacy was defined as???1 zone fluorescein angiographic (FA) improvement, prednisone reduction to?<?10?mg/day with no flares, or both, at 6, 12, and 24?months, and last follow-up...In this retrospective study, medium- and high-dosage IFX+ achieved better inflammation control and visual outcomes versus low-dosage IFX+, with no additional safety concerns, in treating recalcitrant non-infectious inflammatory RV. Early initiation at greater dosages may optimize IFX response, reduce treatment duration, and improve health-related quality of life.
- || tofacitinib / Generic mfg., Humira (adalimumab) / AbbVie
Retrospective data, Review, Journal, HEOR: Comparative effectiveness and safety of tofacitinib vs. adalimumab in patients with rheumatoid arthritis: A systematic review and meta-analysis. (Pubmed Central) - Jun 24, 2025
Tofacitinib was more effective than adalimumab in improving ACR20, VAS, and HAQ-DI, with no significant differences in adverse events or DSA28-CRP improvement. https://www.crd.york.ac.uk/PROSPERO/.
- | Humira (adalimumab) / AbbVie, Tremfya (guselkumab) / J&J
Journal: Successful Treatment of Adalimumab-Induced Pustular Psoriasis With Guselkumab in a Patient With Hidradenitis Suppurativa. (Pubmed Central) - Jun 23, 2025
In patients on this therapy who develop a new-onset diffuse pustular rash, an index of suspicion for this condition should be maintained. TNF-alpha inhibitors should be discontinued if pustular psoriasis develops, with IL-23 inhibitors providing a viable alternative.
- | Journal: Osseous Sarcoidosis: Three Typical Presentations of an Atypical Disease. (Pubmed Central) - Jun 23, 2025
He was treated with methotrexate and infliximab, with significant improvement...Initial treatment included cyclophosphamide, and he is now maintained on azathioprine and adalimumab, which he tolerates well...Despite treatment with infliximab, azathioprine, and low-dose prednisone, she continues to experience neck pain, which is managed with gabapentin...Interestingly, each case also revealed asymptomatic osseous lesions alongside symptomatic sites, suggesting that subclinical skeletal involvement may coexist even in patients presenting with localized symptoms. Early identification of osseous sarcoidosis may be valuable in recognizing patients at risk for more severe or multi-organ disease.
- || Clinical, Journal, Real-world evidence: Real-world Cost per Responder Among Different Classes of Biologics for the Treatment of Psoriasis. (Pubmed Central) - Jun 19, 2025
Tildrakizumab and bimekizumab were excluded due to limited data...Among biologics without biosimilar availability, the lowest CPRs were seen for brodalumab and guselkumab...The relevance of using real-world data, specifically with the use of absolute PASIs instead of relative PASIs, is shown in this study. Additionally, as price fluctuations have the biggest impact on cost-effectiveness, price transparency is essential to effectively guide physicians in selecting a cost-effective treatment strategy.
- || Remicade (infliximab) / J&J, Actemra IV (tocilizumab) / Roche, JW Pharma, Humira (adalimumab) / AbbVie
Review, Journal: A Systematic Review of Anti-TNF and Anti-IL-6 Treatments for Pediatric Takayasu Arteritis: Addressing a Therapeutic Dilemma. (Pubmed Central) - Jun 18, 2025
Despite the higher frequency of anti-TNF drug use, both therapies exhibit similar clinical outcomes, highlighting the potential of tocilizumab as an equally effective alternative in pediatric TAK management. Long-term head-to-head studies are needed to optimize the data regarding biologic treatment strategies in pediatric TAK.
- || PK/PD data, Retrospective data, Journal: Influence of Pharmacokinetic-Pharmacodynamic Failure Mechanisms on Outcomes in Biologic Therapy Sequencing in Inflammatory Bowel Disease: A Retrospective Cohort Study. (Pubmed Central) - Jun 18, 2025
PK-PD failure mechanisms do not appear to influence subsequent treatment outcomes when switching to biologics with different modes of action. Sequencing may rather rely on aspects such as efficacy, safety, and costs.
- || Bimzelx (bimekizumab-bkzx) / UCB, Humira (adalimumab) / AbbVie, Cosentyx (secukinumab) / Novartis
Review, Journal: An update on the medical treatments of hidradenitis suppurativa. (Pubmed Central) - Jun 18, 2025
Modulation of these nonspecific immune and inflammatory signalling pathways is thus becoming increasingly important in numerous on-going therapeutic trials: JAK pathway and complement inhibition, IL-1 blockade, and even inhibition of B-lymphocyte activation pathways. In this article we detail the currently available data and drugs, and their indications in relation to disease stage, while being constantly aware that presently optimal results require multidisciplinary collaboration and often the use of combination therapies.
- || Review, Journal: Systematic review of comparative studies on emerging psoriasis treatments: comparing biologics with biologics, small molecule inhibitors with small molecule inhibitors, and biologics with small molecule inhibitors. (Pubmed Central) - Jun 18, 2025
Although newer biologics offer improved treatment outcomes, further head-to-head trials comparing TYK2, JAK, and PDE4 inhibitors with IL-17 and IL-23 agents are warranted. These findings provide valuable insights to inform clinical decision-making and optimise Psoriasis management strategies.
- | Humira (adalimumab) / AbbVie
Retrospective data, Journal: Outcomes of children with juvenile idiopathic arthritis receiving biological disease-modifying anti-rheumatic drugs: a retrospective single-centre experience from India. (Pubmed Central) - Jun 18, 2025
The most commonly used bDMARD was adalimumab (n = 43, 37.3%)...These observations highlight the need for further surveillance of outcomes of bDMARD use among children with JIA in an LMIC setting. There has been no financial support for this work.
- | Remicade (infliximab) / J&J, Stelara (ustekinumab) / J&J, Humira (adalimumab) / AbbVie
Journal: Gut Microbial Signatures Associated With Clinical Remission in Inflammatory Bowel Disease Treated With Biologics: A Comprehensive Multi-Cohort Analysis. (Pubmed Central) - Jun 17, 2025
A predictive model based on gut microbiota composition may help stratify patients for treatment response. Further investigation of microbiome modulation strategies may enhance therapeutic efficacy.
- || Bimzelx (bimekizumab-bkzx) / UCB
Review, Journal: An evaluation of bimekizumab for the treatment of hidradenitis suppurativa. (Pubmed Central) - Jun 17, 2025
P3
The common side effects of bimekizumab were upper respiratory infections, candida infections and eczematous reactions across all indications. The favorable side effects profile and strong clinical effectiveness proved in clinical trials gave the bimekizumab potential to become the first-choice drug in HS treatment.
- | Valchlor (mechlorethamine gel) / Helsinn, Recordati, Humira (adalimumab) / AbbVie
Biomarker, New trial, HEOR, Real-world evidence: SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY) (clinicaltrials.gov) - Jun 16, 2025
P=N/A, N=840, Not yet recruiting, Sponsor: Leiden University Medical Center